Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Q3 2022 Earnings Presentation
16 slides from Indivior Pharmaceuticals's earnings presentation, Oct 27, 2022
Slide 1: Indivior PLC Q3 2022 Results
Indivior PLC Q3 2022 Results October 27, 2022
Slide 2: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer
Slide 3: Forward-looking statements
Forward-looking statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding the Indivior Group’s financial guidance for 2022 and its medium- and long-term growth outlook; expectations for profitable g
Slide 4: Q3 2022 key messages
Q3 2022 key messages Continued strong execution by the team against our Strategic Priorities; OHS ( strategy delivers first $100m+ NR quarter for SUBLOCADE® (+10% vs. Q2 22) Increased total Group FY 2022 net revenue and adj. operating profit expectations; SUBLOCADE® FY 2022 net revenue now expected
Slide 5: Strategic Priorities update: Q3 2022
Strategic Priorities update: Q3 2022 Grow SUBLOCADE® Diversify Build Our Optimize >$1 bil. Revenue Pipeline Operating Model Q3 22 NR: $108m PERSERIS® Aelis Farma (AEF 0117) Q3 22 reported operating profit: +10% vs. Q2 22 Q3 22 NR: $8m Cannabis Use Disorder: Phase $56m (+47% vs. Q3 21) +14% vs. Q2 22
Slide 6: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer
Slide 7: Q3 2022 financial highlights
Q3 2022 financial highlights Takeaways Operating Profit – Reported and Adjusted1 Reported Adjusted ➤ Top-line growth of 24% vs. Q3 2021 Q3 22 Q3 21 Change Q3 22 Q3 21 Change $ mil • US NR up 32% Net Revenue 232 187 24% 232 187 24% US 189 143 32% 189 143 32% • ROW NR up 9% excluding FX (down ROW2 43
Slide 8: Cash & borrowing position
Cash & borrowing position Cash & Borrowing table Takeaways Total gross cash & investments of $1,035m1: ➤ All cash held in USD ($ in mil.) Q3 22 FY 21 ➤ Strong YTD cash flow from operations excluding Q322 return of cash collateral from ANDA litigation and H1 litigation settlement payments ➤ $66m used
Slide 9: Revised FY 2022 guidance
Revised FY 2022 guidance Additional Top-Line Assumptions FY 22 Guidance1 ($ in mil.) ➤ Underlying BMAT market growth of mid- to high-single digits ➤ US SUBOXONE® Film • Average share expected to remain relatively stable for the Total Net Revenue $890m to $915m (increased from $840m to remaining mont
Slide 10: Capital Markets Day (CMD)
Capital Markets Day (CMD) Investor event setting out Indivior’s roadmap for delivering long-term shareholder value. Presentations from Mark Crossley, CEO, and other key Dec. 7th members of Indivior’s leadership Team. New York City Webcast Link: INDV CMD 2022 In-Person RSVP: InvestorRelations@indivio
Slide 11: Appendix
Appendix ocus on you.
Slide 12: SUBOXONE Film indication and safety information
SUBOXONE® (BUPRENORPHINE AND NALOXONE) SUBLINGUAL FILM (CIII) INDICATION AND USAGE SUBOXONE® Film is indicated for treatment of opioid dependence. SUBOXONE Film should be used as part of a complete treatment plan that includes counseling and psychosocial support HIGHLIGHTED SAFETY INFORMATION Prescr
Slide 13: SUBLOCADE indication and safety information
SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use (CIII) INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment f
Slide 14: About PERSERIS indication and safety information
ABOUT PERSERIS® (risperidone) for extended-release injectable suspension INDICATION PERSERIS® (risperidone) is indicated for the treatment of schizophrenia in adults. WARNING: INCREASED MORTALITY IN ELDERY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed w
Slide 15: Income statement: Q3 2022 vs. Q3 2021
Income statement: Q3 2022 vs. Q3 2021 Q3 2022 Q3 2021 Δ Q3 2022 Q3 2022 Y-o-Y Q3 2021 Q3 2021 Adjustments Adjustments Actual Adjusted (adjusted basis) Actual Adjusted ($ in mil. at Actual FX ) Net Revenues 232 232 187 187 Cost of Sales (40) (40) (26) (26) Gross Profit 192 192 161 161 Gross Margin (%
Slide 16: Income statement: YTD 2022 vs. YTD 2021
Income statement: YTD 2022 vs. YTD 2021 YTD 2022 YTD 2021 Δ YTD 2022 YTD 2022 Y-o-Y YTD 2021 YTD 2021 Adjustments Adjustments Actual Adjusted (adjusted basis) Actual Adjusted ($ in mil. at Actual FX ) Net Revenues 659 659 568 568 Cost of Sales (115) (115) (88) (88) Gross Profit 544 544 480 480 Gross